HEPTARES THERAPEUTICS LIMITED

42 Ashland St, Arlington, Massachusetts, United States

Clinical Trials

0 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

90.9%

Phase 2

9.1%

Trial Status Distribution

Completed

90.9%

Withdrawn

9.1%

Clinical Trials

Trials sponsored by this organization (11)

Study to Investigate the Receptor Occupancy of HTL0014242 Using [18F] FPEB in Healthy Male Subjects

Phase 1

Completed

interventional

Jun 20208 participants

A Study to Assess Safety, Tolerability, and Efficacy of HTL0018318 in Patients With Dementia With Lewy Bodies

Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242

Phase 1

Completed

interventional

Nov 201871 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations

HEPTARES THERAPEUTICS LIMITED

Overview

Trial Phase Distribution

Trial Status Distribution

Clinical Trials

Trials sponsored by this organization (11)

Study to Investigate the Receptor Occupancy of HTL0014242 Using [18F] FPEB in Healthy Male Subjects

A Study to Assess Safety, Tolerability, and Efficacy of HTL0018318 in Patients With Dementia With Lewy Bodies

Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242

Measurement of HTL0016878 in Cerebrospinal Fluid

Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care

A Two Part Study to Assess Safety, PK, PD, and Food Effect of Oral HTL0016878

Pharmacokinetics of Oral Capsule in Healthy Japanese vs. Caucasian Subjects

Relative Bioavailability of HTL0018318 Oral Aqueous Solution Versus Capsules

Approvals

News